Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes

Molecular Vision

Volumn 17, Issue , 2011, Pages 104-112

  Rocher, Nicolas ^a,b   Behar Cohen, Francine ^a,b   Pournaras, Jean Antoine C ^c   Naud, Marie Christine ^b   Jeanny, Jean Claude ^b   Jonet, Laurent ^b   Bourges, Jean Louis ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LECTIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EDEMA; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA TRANSPLANTATION; CORNEAL GRAFT REJECTION; DENATURATION; DRUG DOSAGE FORM COMPARISON; FEMALE; GRAFT REJECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; TREATMENT RESPONSE;

ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; EDEMA; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79551710821     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27:331-371. [PMID: 18653375]
2. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009; 20:158-165. [PMID: 19417570]
3. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than agerelated macular degeneration. Curr Opin Ophthalmol 2009; 20:166-174. [PMID: 19381089]
4. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 2007; 69:925-927. [PMID: 17367957]
5. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008; 27:743-745. [PMID: 18580272]
6. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008; 27:70-73. [PMID: 18245970]
7. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487. [PMID: 7526212]
8. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90:1344-1349. [PMID: 16854824]
9. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127:381-389. [PMID: 19365012]
10. You IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol (Copenh) 2009; 87:653-658. [PMID: 19021596]
11. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007; 35:745-748. [PMID: 17997779]
12. Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009; 50:1659-1665. [PMID: 18997093]
13. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber- associated immune deviation induction. Invest Ophthalmol Vis Sci 1995; 36:2176-85. [PMID: 7558710]
14. Sellami D, Abid S, Bouaouaja G, Ben Amor S, Kammoun B, Masmoudi M, Dabbeche K, Boumoud H, Ben Zina Z, Feki J. Epidemiology and risk factors for corneal graft rejection. Transplant Proc 2007; 39:2609-2611. [PMID: 17954190]
15. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res 2007; 32:1005-1016. [PMID: 18085464]
16. Bachmann BO, Bock F, Wiegand SJ, Maruyama K, Dana MR, Kruse FE, Luetjen-Drecoll E, Cursiefen C. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008; 126:71-77. [PMID: 18195221]
17. Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004; 45:2666-2673. [PMID: 15277490]
18. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008; 145:424-431. [PMID: 18207123]
19. Vassileva PI, Hergeldzhieva TG. Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 2009; 247:1701-1706. [PMID: 19680676]
20. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48:2545-2552. [PMID: 17525183]
21. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol 2009; 247:171-177. [PMID: 18781316]
22. Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlotzer-Schrehardt U, Cursiefen C. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009; 50:2095-2102. [PMID: 19151400]
23. Bourges JL, Lallemand F, Agla E, Besseghir K, Dumont JM, BenEzra D, Gurny R, Behar-Cohen F. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol Vis 2006; 12:1461-1466. [PMID: 17167400]
24. Krause L, Coupland SE, Hoffmann F. The behaviour of ED1- and ED2-positive cells in the rat iris and choroid following penetrating keratoplasty and cyclosporin A therapy. Graefes Arch Clin Exp Ophthalmol 1996; 234:S149-S58. [PMID: 8871167]
25. Holland EJ, Chan CC, Wetzig RP, Palestine AG, Nussenblatt RB. Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model. Cornea 1991; 10:374-380. [PMID: 1935133]
26. Figueiredo FC, Nicholls SM, Easty DL. Corneal epithelial rejection in the rat. Invest Ophthalmol Vis Sci 2002; 43:729-736. [PMID: 11867591]
27. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 1994; 101:1536-1547. [PMID: 8090456]
28. Price MO, Thompson RW Jr, Price FW Jr. Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol 2003; 121:1087-1092. [PMID: 12912684]
29. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998; 17:611-613. [PMID: 9820941]
30. Ambati BK, Patterson E, Jani P, Jenkins C, Higgins E, Singh N, Suthar T, Vira N, Smith K, Caldwell R. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol 2007; 91:505-508. [PMID: 17151056]
31. Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000; 19:526-533. [PMID: 10928772]
32. Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ, Kovesdi I, Rakoczy PE. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12:1299-1310. [PMID: 11440623]
33. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41:2514-2522. [PMID: 10937562]
34. Yu H, Wu J, Li H, Wang Z, Chen X, Tian Y, Yi M, Ji X, Ma J, Huang Q. Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression. Biochem Biophys Res Commun 2007; 361:946-952. [PMID: 17692288]
35. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27:992-995. [PMID: 18812760]
36. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007; 91:804-807. [PMID: 17179168]
37. Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 2008; 115:1916-1922. [PMID: 18718666]
38. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002; 134:348-353. [PMID: 12208245]
39. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 2006; 82:798-806. [PMID: 16324700]
40. Oh JY, Kim MK, Shin MS, Lee HJ, Lee JH, Wee WR. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res 2009; 34:85-91. [PMID: 19219678]
41. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci 2010; 51:4569-4573. [PMID: 20393106]
42. Symes RJ, Poole TR. Corneal graft surgery combined with subconjunctival bevacizumab (avastin). Cornea 2010; 29:691-693. [PMID: 20458243]
43. Foroutan A, Fariba B, Pejman B, Mahmoud J, Khalil GF, Arash EA, Foroutan P. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty. Cornea 2010; 29:1268-1272. [PMID: 20802316]
44. Mackenzie SE, Tucker WR, Poole TR. Bevacizumab (avastin) for corneal neovascularization-corneal light shield soaked application. Cornea 2009; 28:246-247. [PMID: 19158579]
45. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008; 27:1195-1199. [PMID: 19034142]
46. Weijtens O, Schoemaker RC, Lentjes EG, Romijn FP, Cohen AF, van Meurs JC. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology 2000; 107:1932-1938. [PMID: 11013202]
47. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974; 63:333-338. [PMID: 4820359]
48. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000; 27:558-562. [PMID: 10874518]
49. Brereton HM, Taylor SD, Farrall A, Hocking D, Thiel MA, Tea M, Coster DJ, Williams KA. Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol 2005; 89:1205-1209. [PMID: 16113383]
50. Thiel MA, Coster DJ, Standfield SD, Brereton HM, Mavrangelos C, Zola H, Taylor S, Yusim A, Williams KA. Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 2002; 128:67-74. [PMID: 11982592]
51. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50:4807-4813. [PMID: 19324856]
52. Saravia M, Zapata G, Ferraiolo P, Racca L, Berra A. Anti- VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis. Graefes Arch Clin Exp Ophthalmol 2009; 247:1409-1416. [PMID: 19655160]
53. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113:1040-1050. [PMID: 15057311]
54. Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008; 27:349-352. [PMID: 18362666]
55. Miyamoto N, de Kozak Y, Normand N, Courtois Y, Jeanny JC, Benezra D, Behar-Cohen F. PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema. Ophthalmic Res 2008; 40:203-207. [PMID: 18421240]
56. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen F. Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 2005; 46:4072-4078. [PMID: 16249482]
57. Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 2002; 277:10445-10451. [PMID: 11784713]
58. Bourges JL, Torriglia A, Valamanesh F, Benezra D, Renard G, Behar-Cohen FF. Nitrosative stress and corneal transplant endothelial cell death during acute graft rejection. Transplantation 2007; 84:415-423. [PMID: 17700169]
59. Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci 2000; 41:1063-1069. [PMID: 10752942]